Hong Kong-listed Mabpharm Limited filed its Monthly Return for Equity Issuer for the period ended 31 May 2026, confirming a stable share capital structure with no new issuances, cancellations or treasury share transactions during the month.

Authorised Share Capital • Authorised share capital remained unchanged at 50.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to USD 5.00 million.

Issued Share Capital • Issued shares (excluding treasury shares) stayed at 4.12 billion, identical to the previous month’s closing balance. • The company reported zero treasury shares in both the opening and closing balances.

Public Float Compliance • Mabpharm affirmed compliance with the Main Board’s 25 percent minimum public-float requirement as at 31 May 2026.

Share Option Scheme Activity • Outstanding options under the 10 August 2018 scheme totalled 72.67 million, with no options exercised, lapsed or cancelled in May. • If fully exercised, these options could increase the issued share base by up to 72.67 million shares, representing roughly 1.8 percent of existing issued shares.

Capital Structure Summary • Authorised share capital: USD 5.00 million (50.00 billion shares). • Issued share capital: 4.12 billion shares. • Treasury shares: none. • Net change in issued or treasury shares for May 2026: nil.

The filing, signed by Secretary Tsang Ho Yin on 2 June 2026, indicates a month of capital stability for Mabpharm, with no financing or dilution events recorded.